the - 医索

找到约 965 条结果

Enfortumab Vedotin in the HR HER2-and Triple-Negative Breast CancerCohorts of EV-202

医客学院 - 会议报告集

Enfortumab Vedotin in the HR HER2-and Triple-Negative Breast CancerCohorts of EV-202 - 副本

医客学院 - 会议报告集

Elucidating the lmmune Active State of HR HER2.MammaPrint High 2 Early Breast Cancer

医客学院 - 会议报告集

DESTINY-Breast07dose-expansion analysis ofT-DXd monotherapy and T-DXd pertuzumab inpatients with previously untreated HER2 mBC

医客学院 - 会议报告集

Datopotamab deruxtecan (Dato-DXd)vs chemotherapy inpreviously-treated inoperable or metastatic hormonereceptor-positive, HER2-negative (HR HER2-) breast cancerPatient-reported outcomes(PROs) from

医客学院 - 会议报告集

Comparison antitumor efficacy Of first-line Of Palbociclib, Ribociclib or Abemaciclib in patients with HR HER2-aBC results of the multicenter, real-world,Italian study PALMARES-2

医客学院 - 会议报告集

Cognitive function in women with HR advanced breast cancer treated withendocrine therapy ± CDK46 inhibitors

医客学院 - 会议报告集

Association of MammaPrint index and 3-yearoutcome of patients in the FLEX Registry trial withHR HER2-early-stage breast cancer treated withchemotherapy with or without anthracycline

医客学院 - 会议报告集

Abstract LBA509Rates of pathologic complete response(pCR)after neoadjuvant datopotomab deruxtecan(Dato-DXd) Results from the l-SPY 2.2trial

医客学院 - 会议报告集

Abemaciclib plus fulvestrant vs fulvestrant alone for HR HER2-advanced breast cancer following progression onprior CDK46 inhibitor plus endocrine therapy Primaryoutcome of the Phase 3 postMONARCH

医客学院 - 会议报告集

今日实时热搜